Tag: investment
-
Venture Firm Funding Univ. Blood Diagnostics Technology
23 May 2016. A life sciences venture capital company is funding development of a technology at an Israeli research lab using DNA from blood tests to diagnose a range of diseases. Aurum Ventures is providing $1.2 million to Hebrew University of Jerusalem, through its technology transfer affiliate Yissum Research Development Company, for the university lab…
-
Neurological Biotech Raises $65M in Venture Funds
10 May 2016. A biotechnology company designing treatments for neurological disorders caused by rigidity in nerve cell synapses, is raising $65 million in its first venture funding round. Aptinyx Inc. in Evanston, Illinois, is a spin-off enterprise that formed when Naurex Inc., another biotech company, was acquired by drug maker Allergan plc in September 2015.…
-
Medical Google Glass Start-Up Raises $17M in Venture Funds
25 April 2016. A company building a system that allows doctors to automatically create patient notes with Google Glass added $17 million in its second full round of venture funding. Augmedix Inc., a 2 year-old enterprise in San Francisco, says the new financing will enable the company to scale-up its service across the country to…
-
Intrexon Spin-Off Developing Type 1 Diabetes Therapy
4 April 2016. A new subsidiary of the synthetic biology company Intrexon Corp. is creating a pill for people with type 1 diabetes to stop the disease’s damage in its early stages. The enterprise, known as Intrexon T1D Partners LLC, is a joint venture between Intrexon, in Germantown, Maryland, and White Rock Capital Partners a…
-
Organ Chip Spin-Off Gains $28M in Venture Funds
28 March 2016. A two year-old company developing chip devices that simulate human organs is adding $28 million in venture capital to its treasury. This is the second venture funding round for Emulate Inc., in Boston, a spin-off enterprise from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate Inc. creates plastic chip…
-
Cancer Diagnostics Company Raises $12.3M in IPO
18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced at $3.25. VolitionRx designs…
-
Company Hosts Cancer Genome Cloud, Raises $45 Million
16 February 2016. Seven Bridges Genomics, a computational biology company, unveiled its cloud-based cancer genome data sets, in one of three pilot tests for National Cancer Institute. The Cambridge, Massachusetts enterprise also raised $45 million in its first venture funding round. National Cancer Institute, part of National Institutes of Health, aims to make the Cancer…
-
$45M Raised by Protein Folding Drug Discovery Company
10 February 2016. A company discovering new treatments that address errant folding of proteins causing neurological disorders raised $45 million in its first venture funding round. Yumanity Therapeutics, a spin-off enterprise from the Whitehead Institute affiliated with MIT, started in December 2014 and aims to discover therapies for neurodegenerative diseases caused by misfolded proteins. Yumanity…
-
Genome-Editing Company Raises $94 Million in IPO
3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, the stock is…
-
Juno Acquires Biotech, Licenses Cell Sequencing Tech
11 January 2016. Juno Therapeutics is gaining single-cell sequencing technology for cancer immunotherapies through the buy-out of biotechnology company AbVitro Inc., and licensing part of that technology to pharmaceutical company Celgene Corp. The AbVitro acquisition is valued at about $125 million, while financial details of the licensing deal with Celgene are not disclosed. Juno Therapeutics,…